Also known as

Bremelanotide · Vyleesi (brand context) · Melanocortin agonist

Overview

PT-141 (bremelanotide) is a melanocortin receptor agonist studied in arousal-signaling models for both sexes and approved in some jurisdictions for specific female HSDD indications. Research catalogs also use it for central melanocortin pathway work.

This page frames laboratory endpoints only—not prescribing or dosing information. Left Turn Adventures supplies this compound for laboratory and research use only.

Proven benefits

Note: Preclinical / literature endpoints for labs — not established human treatment benefits. Not a protocol.

 Central melanocortin arousal-signaling endpoints

• MC3R/MC4R pathway markers in behavioral models

• • Sex-difference research readouts where studied

• • Comparative pharmacology versus Melanotan-class agonists

• • Autonomic co-markers reported in melanocortin literature

Results timeline

Note: Illustrative research-observation windows — not a clinical schedule. No dosing.

• Week 1–2: Early melanocortin or gonadal-axis signaling in acute models.

• • Week 3–4: Clearer arousal, pigmentation, or hormone-axis markers in short research windows.

• • Month 2–3: More stable pathway and behavioral endpoints in extended preclinical designs.

• • Month 3–6: Sustained melanocortin or reproductive-axis observations where longer windows are used.

The catalog, not a clinic

For laboratory and research use only. Not for human or animal consumption. Products are sold solely to qualified researchers and licensed laboratories. No dosing or reconstitution on this page.